Page 829 - First Aid for the USMLE Step 1 2020, Thirtieth edition [MedicalBooksVN.com]_Neat

INDEX INDEX 785

NNRTIs, 203 peptic ulcer disease and, 380 Null hypothesis, 263 “OK gesture,” 451
Nocardia spp rheumatoid arthritis, 466 Number needed to harm (NNH), Olanzapine, 573
aerobic culture requirements, 126 for sialadenitis, 376 258 Olfaction
comparison with Actinomyces spp, Non-ST-segment elevation MI Number needed to treat (NNT), hallucinations, 559
139 (NSTEMI) 258 limbic system in, 499
effects and treatment, 139 diagnosis of, 306 Nursemaid’s elbow, 461 Olfactory nerve (CN I), 506
necrosis and, 209 STEMI vs, 304 Nutcracker syndrome, 363 Oligoclonal bands, 523
sulfonamides for, 194 treatment, 307 Nutmeg liver, 309, 392 Oligodendrocytes, 494
urease-positive, 127 Noradrenergic drugs, 574 Nutrition, 65–72 Oligodendroglia, 490
Ziehl-Neelsen stain, 125 Norepinephrine (NE) Nyctalopia, 66 in multiple sclerosis, 494
Nocturia, 654 adrenal medulla secretion, 327 Nystagmus Oligodendrogliomas, 526
Nocturnal enuresis, 329 amphetamines and, 239 cerebellum, 499 Oligohydramnios, 578, 641
Nodes of Ranvier, 494 bupropion effect on, 576 common lesions with, 511 Oligomenorrhea, 633
Nodular phlebitis, 314 changes with disease, 495 Friedreich ataxia, 531 Oligomycin, 78
Nodular sclerosis lymphoma, 429 circadian rhythm, 497 internuclear ophthalmoplegia, Oligospermia, 400
Noise-induced hearing loss, 533 direct sympathomimetic, 242 543 Olive-shaped mass, 359
Nonadherent patients, 268 isoproterenol vs, 243 PCP, 571 Omalizumab, 122, 687
Nonalcoholic fatty liver disease, 389, male sexual response, 627 phenytoin, 544 Ombitasvir, 204
390, 391, 392 MAO inhibitor effects, 575 stroke and, 514 Omental foramen, 361
Nonbacterial endocarditis, 311 opioid effect on, 551 Nystatin, 199 Omeprazole, 399
Nonbacterial thrombotic pheochromocytoma secretion, 350 Omphalocele, 358
endocarditis, 228 release regulation, 239 O Omphalomesenteric cysts, 384
Nonbenzodiazepine hypnotics, 546 REM sleep and, 497 Obesity Omphalomesenteric (vitelline) duct,
Noncaseating granulomas vitamin B and, 67 amphetamine for, 242 618
6
sarcoidosis, 676 Norethindrone, 657 anovulation with, 645 Onchocerca volvulus, 159
Noncommunicating hydrocephalus, Norfloxacin, 195 cholelithiasis and, 396 Oncocytoma (renal), 605
522 Normal distribution, 262 DM type 2 and, 347 Oncogenes, 224
Noncompetitive agonists, 234 Normal flora esophageal cancer and, 378 Oncogenic microbes, 226
Noncompetitive antagonist, 234 colonic, 137 hypertension risk factors, 300 Ondansetron, 400
Noncompetitive inhibitors, 230 female genital tract, 136 hypoventilation syndrome, 679 torsades de pointes, 248
Noncompliant patients, 268 GI tract, 127 lateral femoral cutaneous nerve, 1,25-(OH) D 3
2
Nondepolarizing neuromuscular neonates, 178 452 kidney endocrine function, 589
blocking drugs, 551 oropharynx, 136 osteoarthritis/rheumatoid arthritis, “100-day cough,” 132
Nondominant parietal cortex lesions, skin, 135 466 Onion skin periosteal reaction, 465
511 Normal pressure hydrocephalus, 522 renal cell carcinoma association, Onychomycosis
Non-frameshift mutations Normal splitting, 289 605 terbinafine, 199
deletions, 61 Normocytic anemia, 421 sleep apnea, 679 tinea unguium, 152
Nonhemolytic, normocytic anemia, Norovirus, 167 stress incontinence and, 599 Oocysts
421 Northern blot, 53 Obligate intracellular organisms, acid-fast stain, 155
Non-Hodgkin lymphoma, 430 Nortriptyline, 575 127 Toxoplasmosis, 156
corticosteroids, 120 Nosocomial infections, 274 Observational studies, 256 Ziehl-Neelsen stain, 125
Hashimoto thyroiditis and, 341 Acinetobacter baumannii, 142 errors in, 260–261 Oogenesis, 631
hepatitis C, 173 Ebola, 171 Observer-expectancy bias, 260 Oophorectomy, 625
HIV-positive adults, 177 enterococci, 137 Obsessive-compulsive disorder Open-angle glaucoma, 536
Hodgkin lymphoma vs, 429 Klebsiella, 145 (OCD) carbachol for, 240
oncogenes and, 224 MRSA, 135 diagnostic criteria/treatment, 563 pilocarpine for, 240
rituximab for, 443 pneumonias, 179 drug therapy for, 572 Operant conditioning, 554
vinca alkaloids for, 441 Pseudomonas aeruginosa, 143 SSRIs for, 575 Ophthalmology, 534–541
Nonhomologous end joining, 40 risk factors, 185 Tourette syndrome and, 557 Ophthalmoplegia
Nonmaleficence (ethics), 265 UTIs as, 181 venlafaxine for, 575 cavernous sinus syndrome, 542
Nonmegaloblastic macrocytic Notochord, 490, 612–613 Obsessive-compulsive personality common lesions with, 511
anemia, 420 postnatal derivative of, 282 disorder, 566 internuclear, 543
Nonnormal distributions, 262 Novobiocin Obstructive jaundice, 398 Wernicke-Korsakoff syndrome,
Nonoverlapping genetic code, 37 gram-positive antibiotic test, 134 Obstructive lung diseases, 674–675 571
Nonreceptor tyrosine kinase, 337 Staphylococcus epidermidis, 135 flow volume loops in, 673 Opioid analgesics, 551
Non-REM sleep stages, 497 NRTIs, 203 Obstructive shock, 310 agonists, 551
Nonselective antagonists, 245 NS3/4A inhibitors, 204 Obstructive sleep apnea, 679 Beers criteria, 247
Nonsense mutations, 39 NS5A inhibitors, 204 pulsus paradoxus in, 310 detoxification and relapse
Nonsteroidal anti-inflammatory drugs NS5B inhibitors, 204 Obturator nerve, 452 prevention, 576
(NSAIDs), 486 Nuchal translucency, 63 Occipital cortex, 515 intoxication and withdrawal, 570
acute pericarditis, 313 Nucleic acids Occipital lobe, 501 mechanism and use, 551
aplastic anemia, 250 pathogen-associated molecular Occipital sinus, 503 mixed agonist/antagonist
Beers criteria, 247 pattern (PAMP), 99 Occult bleeding, 387 analgesics, 552
calcium pyrophosphate deposition Nucleosome, 34 FOBT for, 388 receptor binding, 234
disease, 467 Nucleotide excision repair, 40 Octreotide, 371, 400 sleep apnea, 679
colorectal cancer Nucleotides, 35 acromegaly, 339 toxicity treatment, 248
chemopreventative, 389 deamination reactions, 35 GH excess, 329 Opisthotonos
esophagitis from, 377 synthesis, 72 hypothalamic/pituitary drugs, 354 tetanospasmin, 138
gastritis with, 379 Nucleus accumbens, 495 Ocular motility, 540 Opponens digiti minimi muscle, 450
GFR effects of, 589 Nucleus ambiguus, 506 Oculomotor nerve (CN III), 506 Opponens pollicis muscle, 450
gout, 467, 487 Nucleus cuneatus, 509 ocular motility, 540 Opportunistic fungal infections,
headaches, 518 Nucleus pulposus palsy of, 513, 541 153–154
interstitial nephritis, 249 collagen in, 50 pupillary contraction, 539 Oppositional defiant disorder, 557
loop diuretics and, 608 fetal precursor, 282 Odds ratio (OR), 256, 258 Opposition (thumb), 450, 451
misoprostol use with, 399 Nucleus tractus solitarius (NTS), Ofloxacin, 195 Opsoclonus-myoclonus syndrome,
osteoarthritis, 466 496 Okazaki fragments, 38 228, 350

FAS1_2019_21_Index_749-806.indd 785 11/21/19 12:27 PM